Subjects

Your browser does not support JavaScript, or its support is disabled. Some features may not be available.

Progress in experimental cancer immunotherapy - CCOC5927

Title:	Pokroky v experimentální imunoterapii nádorů
Guaranteed by:	Department of Immunology and Clinical Biochemistry 3FM CU (12-IMUN)
Faculty:	Third Faculty of Medicine
Actual:	from 2009
Semester:	summer
Points:	1
E-Credits:	1
Examination process:	summer s.:
Hours per week, examination:	summer s.:0/15, C [HS]
Extent per academic year:	15 [hours]
Capacity:	unknown / unknown (unknown)
Min. number of students:	unlimited
4EU+:	no
Virtual mobility / capacity:	no
Key competences:
State of the course:	not taught
Language:	Czech
Teaching methods:	full-time
Teaching methods:	full-time
Level:
Note:	course can be enrolled in outside the study plan

Guarantor:	RNDr. Katarína Hulíková, Ph.D.
Attributes:	Modul IID

Examination dates Schedule

Annotation -

Last update: HULIKOVA (30.05.2008)

Compulsory optional course for students of the third year

Aim of the course -

Last update: HULIKOVA (30.05.2008)

Aim of subject is to inform students about antitumor immune response and possibilities of cancer immunotherapy with emphasis on the newest knowledge.

Literature -

Last update: HULIKOVA (30.05.2008)

Journals: Nature Immunology, Nature Cancer Reviews, Cancer Immunol Immunotherapy, Jounal of Immunology, Immunological Reviews, Current Opinion in Immunology, Clinical Cancer Research, Jornal of Controlled Release,...

Teaching methods -

Last update: HULIKOVA (22.07.2008)

lectures and discussions

Requirements to the exam - Czech

Last update: HULIKOVA (22.07.2008)

Podmínkou získání zápočtu je 10 minutová prezentace na téma související s obsahem kurzu (PowerPoint nebo jen ústní sdělení). Prípustná je jedna absence bez udání důvodu, absence z důvodu nemoce (potvrzení od lékaře)se akceptuje bez jakékoliv formy náhrady.

Syllabus -

Last update: HULIKOVA (30.05.2008)

1. Cancer etiology (carcinogens, mechanisms of tumor transformation, characteristic features of tumor cells)

2. Tumor antigens, antitumor immune response, tumor escape

3. Possibilities of cancer therapy, history of cancer immunotherapy, methods for immune response monitoring during cancer immunotherapy, vaccine strategies for cancer immunotherapy

4. Cancer immunotherapy with polymer-bound drugs

5. Monoclonal antibodies in cancer immunotherapy (hybridoma technology, chimeric and humanized monoklonal antibodies)

6. Cancer immunotherapy based on the cellular immunity (LAK cells, tumor infiltrating lymphocytes, antigen specific T cells, dendritic cells)

7. Cytokines in cancer immunotherapy, the newest approaches used in cancer immunotherapy

8. Students' presentations